Steve Elms Acquires 11,085 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Steve Elms purchased 11,085 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the transaction, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This represents a 3.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Marker Therapeutics Price Performance

Marker Therapeutics stock traded up $0.03 during midday trading on Thursday, hitting $3.41. The company’s stock had a trading volume of 46,092 shares, compared to its average volume of 31,342. Marker Therapeutics, Inc. has a 12 month low of $2.44 and a 12 month high of $6.16. The stock’s 50-day moving average price is $3.71 and its 200-day moving average price is $3.83.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH raised their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC purchased a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned about 0.22% of Marker Therapeutics as of its most recent filing with the Securities & Exchange Commission. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.